when is retatrutide coming to market 🎙️ NEW EPISODE: Retatrutide—The Triple Agonist *Not licensed* Will this replace the current GLP-1 in the market., This triple receptor agonist (GIP/GLP-1/glucagon) showing unprecedented results in The retatrutide drug is manufactured

Additional metabolic pathways and regulatory factors also influence cellular susceptibility to ferroptosis

Drug: GZR18 GZR18, developed by Gan and Lee Pharmaceuticals, USA, is currently undergoing a Phase II trial to assess its efficacy and safety for weight management in obese or overweight individuals

That's where GLP-1 supplements come in marketed as a more natural, noninjectable way to tap into similar benefits

The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss

Recent studies have pointed to disruptions in various metabolic pathways involved in seizure initiation, propagation, and resistance to ASMs 7,8

SURPASS-CVOT is unique, in that it compares the dual incretin agonist with a GLP-1 RA that has been shown to have cardiovascular benefit in people with type 2 diabetes and high risk ASCVD